纵横研报
Ticker Detail

688488.SHG

¥17.17+9.22% 艾迪药业 Biotechnology
00Reports China 医疗健康
Jiangsu Aidea Pharmaceutical Co Ltd
医疗健康 · 生物科技

Jiangsu Aidea Pharmaceutical Group Co., Ltd. develops, produces, and sells pharmaceutical products in China and internationally. It offers anti-HIV drugs and human-derived proteins. The company also provides anti-virus products, such as ainuovirine tablets; urinary protein products, including crude product/intermediate of ulinastatin, urinary kallidinogenase, and urokinase; sennae folium granules; and baicillus cereus tablets. It also exports its products. The company was formerly known as Jiangsu Aidea Pharmaceutical Co., Ltd. and changed its name to Jiangsu Aidea Pharmaceutical Group Co., Ltd. in July 2025. Jiangsu Aidea Pharmaceutical Group Co., Ltd. was founded in 2009 and is headquartered in Yangzhou, China.

MARKET 市值 6.03B CNY 52W ¥11.4 – ¥22.55 EODHD · Q 2026-03-31 · 同步 2026-07-12
QUALITY PEG 营收 YoY -10.0% ROE -0.3% 营业利润率 11.8% 净利润率 -3.9%

暂无相关研报

数据库中已收录该标的的基本面数据,可发起一份定制研报。

CUSTOM RESEARCH · 定制研报 没找到完全契合的标的?让我们替你做一份。 告诉我们你关心的标的与偏好,1 个工作日内在站内上线。 开始定制